UK markets closed
NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
82.84 +0.94 (+1.15%) GOLD FUTURES
2,338.10 -8.30 (-0.35%) DOW
38,462.80 +222.82 (+0.58%) Bitcoin GBP
53,619.85 +395.80 (+0.74%)
Cipla Limited (CIPLA.NS)
NSE - NSE Real-time price. Currency in INR
Add to watchlist
At close: 03:30PM IST
| Previous close | 1,354.85 |
| Open | 1,369.75 |
| Bid | 1,346.70 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 1,344.50 - 1,369.75 |
| 52-week range | 896.30 - 1,519.00 |
| Volume | |
| Avg. volume | 1,539,594 |
| Market cap | 1.087T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 29.32 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.50 (0.63%) |
| Ex-dividend date | 21 Jul 2023 |
| 1y target est | N/A |
- PR Newswire
Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products
Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products
© 2024 Yahoo. All rights reserved.